Last reviewed · How we verify

Oral levetiracetam

Children's Hospital of Fudan University · FDA-approved active Small molecule

Oral levetiracetam is a Antiepileptic agent Small molecule drug developed by Children's Hospital of Fudan University. It is currently FDA-approved for Epilepsy (adjunctive therapy for partial-onset seizures), Epilepsy (adjunctive therapy for myoclonic seizures), Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures). Also known as: Keppra, Iracet Injection, Neurocet Injection, levetiracetam.

Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release.

Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release. Used for Epilepsy (adjunctive therapy for partial-onset seizures), Epilepsy (adjunctive therapy for myoclonic seizures), Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures).

At a glance

Generic nameOral levetiracetam
Also known asKeppra, Iracet Injection, Neurocet Injection, levetiracetam
SponsorChildren's Hospital of Fudan University
Drug classAntiepileptic agent
TargetSV2A (synaptic vesicle protein 2A)
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Levetiracetam is a pyrrolidone derivative that binds to the synaptic vesicle protein SV2A, which is involved in vesicle exocytosis and neurotransmitter release. This binding reduces the release of excitatory neurotransmitters and stabilizes neuronal membranes, thereby decreasing seizure susceptibility. The exact mechanism is not fully elucidated, but SV2A binding is considered the primary molecular action responsible for its antiepileptic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Oral levetiracetam

What is Oral levetiracetam?

Oral levetiracetam is a Antiepileptic agent drug developed by Children's Hospital of Fudan University, indicated for Epilepsy (adjunctive therapy for partial-onset seizures), Epilepsy (adjunctive therapy for myoclonic seizures), Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures).

How does Oral levetiracetam work?

Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release.

What is Oral levetiracetam used for?

Oral levetiracetam is indicated for Epilepsy (adjunctive therapy for partial-onset seizures), Epilepsy (adjunctive therapy for myoclonic seizures), Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures).

Who makes Oral levetiracetam?

Oral levetiracetam is developed and marketed by Children's Hospital of Fudan University (see full Children's Hospital of Fudan University pipeline at /company/children-s-hospital-of-fudan-university).

Is Oral levetiracetam also known as anything else?

Oral levetiracetam is also known as Keppra, Iracet Injection, Neurocet Injection, levetiracetam.

What drug class is Oral levetiracetam in?

Oral levetiracetam belongs to the Antiepileptic agent class. See all Antiepileptic agent drugs at /class/antiepileptic-agent.

What development phase is Oral levetiracetam in?

Oral levetiracetam is FDA-approved (marketed).

What are the side effects of Oral levetiracetam?

Common side effects of Oral levetiracetam include Somnolence, Asthenia/fatigue, Dizziness, Headache, Behavioral/mood changes, Ataxia.

What does Oral levetiracetam target?

Oral levetiracetam targets SV2A (synaptic vesicle protein 2A) and is a Antiepileptic agent.

Related